SOURCE: TOPIGEN Pharmaceuticals

February 09, 2006 08:30 ET

TOPIGEN's CEO to Present at BIO CEO & Investor Conference

MONTREAL and RANDOLPH, NJ -- (MARKET WIRE) -- February 9, 2006 -- TOPIGEN Pharmaceuticals Inc., a biopharmaceutical company specializing in innovative respiratory therapeutics, today announced that Dr. Paul Wotton, President and Chief Executive Officer, will be presenting at the 8th Annual BIO CEO & Investor Conference in New York City (February 14-15, 2006), at the Waldorf Astoria Hotel. Dr. Wotton is presenting on Wednesday, February 15th, at 11:30 AM in the Park Avenue Suite Center/North and will be available for one-on-one meetings during the conference.

Dr. Wotton's presentation will be webcast and available, both live and for replay, via the Company's website at www.topigen.com.

The 8th Annual BIO CEO & Investor Conference, one of the year's largest life science investor events, provides a forum for private and public companies to present progress on their development programs with investors and the financial community.

TOPIGEN is a leading biopharmaceutical respiratory company with two drugs undergoing Phase II clinical trials for the treatment of COPD (TPI-1020) and asthma (TPI-ASM8). The presentation will include an update of the company's progress on the two programs.

TPI-1020 is a novel, proprietary nitric-oxide donating derivative of budesonide. TOPIGEN screened, evaluated and validated this small molecule using the company's discovery expertise and demonstrated novel activity in models of COPD. In October 2005, TOPIGEN in-licensed North American rights for the compound from NicOx S.A., for COPD and other respiratory diseases with an option for worldwide rights.

TPI-ASM8 is a first-in-class, inhaled drug that combines two oligonucleotides into a single product delivered directly to the lungs for knock-down of cell receptors involved in the development of chronic asthma. This pioneering approach addresses the issue of pathway redundancy by blocking the expression of specific genes in multiple pathways responsible for asthma and allergic inflammation.

About TOPIGEN

TOPIGEN is a privately held biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. TOPIGEN's pipeline includes small molecule and RNA-based therapeutics. The Company's Phase II products and research programs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This pioneering approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis. For more detailed information on TOPIGEN visit www.topigen.com.

For more information about BIO CEO visit http://ceo.bio.org/opencms/ceo/2006/index.jsp

Contact Information

  • Contact:
    G. John Mohr
    TOPIGEN Pharmaceuticals, Inc.
    (973) 809-5582
    Email Contact

    Media:
    Bryan P. Murphy
    LaVoie Group
    (781) 596-0200 X105
    Email Contact